Status:

COMPLETED

Prephage - Faecal Bacteriophage Transfer for Enhanced Gastrointestinal Tract Maturation in Preterm Infants - Donor Study

Lead Sponsor:

Rigshospitalet, Denmark

Collaborating Sponsors:

Lise Aunsholt, Neonatologist, Clinical Professor

Conditions:

Feeding Patterns

Microbial Colonization

Eligibility:

All Genders

Brief Summary

PrePhage - Fecal bacteriophage transfer for enhanced gastrointestinal tract maturation in preterm infants This pilot triol has the primary goal of demonstrating the safety of transferring viruses and...

Detailed Description

Detailed Description: PrePhage - Fecal bacteriophage transfer for enhanced gastrointestinal tract maturation in preterm infants This pilot trial aims to investigate if fecal filtrate transfers (FFT)...

Eligibility Criteria

Inclusion

  • Inclusion criteria for infants
  • The donor must be of term (\>37+0 weeks GA, \< 41+0 weeks GA),
  • Be born vaginally with no maternal pre-birth infection,
  • Be exclusively breastfed un till fulfilled donation at 4 weeks of age,
  • Have no known predisposition for disease.
  • Exclusion criteria for infants
  • Antibiotic exposure before collection of faecal material for donation,
  • Disease between time of birth and collection of feces for donation,
  • Major congenital anomalies or birth defects, perinatal asphyxia, need for mechanical ventilation or cardiovascular support before time of inclusion.
  • Positive stool sample for C. difficile toxin, parasites or other pathogens
  • Positive HIV, HBV, or HCV or CMV
  • Parents who do not want to know the HIV, HBV or HCV status of the child
  • Inclusion criteria for mothers
  • Women aged 18-45 and currently healthy
  • No continuous medical consumption with effects on microbiome
  • Non-smoking
  • Ability to give informed consent
  • Exclusion criteria for mothers
  • Known or high risk of infectious disease such as HIV, HBV, or HCV
  • Positive CMV IgM during pregnancy
  • Positive stool sample for C. difficile toxin, parasites or other pathogens
  • Systemic antibiotic treatment \< 1 months prior to study
  • New tattoo \< 1 month prior to study
  • Risky sexual behavior
  • Gestational diabetes
  • Family history of inflammatory bowel disease

Exclusion

    Key Trial Info

    Start Date :

    April 1 2022

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    March 20 2024

    Estimated Enrollment :

    38 Patients enrolled

    Trial Details

    Trial ID

    NCT05272566

    Start Date

    April 1 2022

    End Date

    March 20 2024

    Last Update

    June 4 2024

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Gustav R Jakobsen

    Copenhagen, Denmark, 2100